Results 251 to 260 of about 152,721 (288)
Some of the next articles are maybe not open access.
Cetuximab In Squamous Cell Carcinoma of the Head and Neck
Future Oncology, 2006Surgery and radiotherapy are the standard treatment options for patients with squamous cell carcinoma of the head and neck (SCCHN). Chemotherapy and chemoradiotherapy are new alternatives for locally advanced disease, particularly induction chemotherapy for patients with unresectable tumors.
Ricardo, Hitt +2 more
openaire +2 more sources
Squamous cell carcinoma of the head and neck in children
International Journal of Pediatric Otorhinolaryngology, 2019To discuss the presentation, evaluation, and management of squamous cell carcinoma of the head and neck in the pediatric population.Medical records of pediatric (≤20 years) patients treated for squamous cell carcinoma of the head and neck between 1996 and 2016 were reviewed.
Natasha D. Dombrowski +6 more
openaire +2 more sources
Angiogenesis in head and neck squamous cell carcinoma
Clinical Otolaryngology and Allied Sciences, 2000Tumour angiogenesis has recently attracted a great deal of attention as a critical part of oncogenesis and a necessary prerequisite for a malignant phenotype. Research into this process not only offers new insights into tumour biology but is also leading to the development of realistic novel and minimally toxic anti-tumour therapies.
J J, Homer, J, Greenman, N D, Stafford
openaire +2 more sources
Afatinib in squamous cell carcinoma of the head and neck
Expert Opinion on Pharmacotherapy, 2016Recently new data on the efficacy of afatinib in head and neck squamous cell carcinoma (HNSCC) have been published.We searched the literature for published and ongoing studies with afatinib in HNSCC. Phase I data and results of phase II and III studies of afatinib in HNSCC are discussed.
Specenier, Pol, Vermorken, Jan
openaire +3 more sources
The economics of squamous cell carcinoma of the head and neck
Current Opinion in Otolaryngology & Head & Neck Surgery, 2007The current review presents a brief overview of the recent literature on the costs of squamous cell carcinoma of the head and neck (SCCHN), one of the most common forms of cancer. SCCHN is a relatively deadly disease. Approximately 50% of patients survive to 5 years, and surgery and chemoradiotherapy can leave survivors with pain, disfigurement, and ...
Joseph, Menzin +2 more
openaire +2 more sources
Pharmacotherapy of head and neck squamous cell carcinoma
Expert Opinion on Pharmacotherapy, 2009The clinical management of locally advanced head and neck squamous cell carcinoma (HNSCC) is a challenging problem and requires a multidisciplinary approach. Historically, locally advanced HNSCC has been primarily managed with surgery and radiation (RT).
Quintin, Pan +2 more
openaire +2 more sources
Pharmacotherapy for squamous-cell carcinoma of the head and neck
Expert Opinion on Pharmacotherapy, 2011squamous-cell carcinoma of the head and neck (HNSCC) is one of the most common malignancies, the treatment of which constitutes a therapeutic challenge.the purpose of this review is to provide an update on the pharmacotherapy for the treatment of HNSCC focusing mainly on molecular-targeted therapies.
Giorgos, Papaspyrou +2 more
openaire +2 more sources
Stem cells in head and neck squamous cell carcinoma
British Journal of Oral and Maxillofacial Surgery, 2011The existence of a small subpopulation of tumourigenic cancer stem cells in the bulk of human head and neck squamous cancers (SCC) has been recognised in recent reports. This subpopulation has self-renewal properties and is responsible for the production of differentiated daughter cells that form the bulk of the tumour.
Kaveh, Shakib +2 more
openaire +2 more sources
Head and neck squamous cell carcinoma: Better to be young
Otolaryngology - Head and Neck Surgery, 1997Most head and neck squamous cell carcinoma patients are elderly, with few younger than 40 years. Controversy exists in the literature regarding outcomes for younger patients. The goal of this research project was to compare baseline features and outcomes for young patients (≤40 years), middle‐aged patients (41‐64 years), and old patients (≥65 years ...
P D, Lacy +3 more
openaire +2 more sources
Nivolumab in squamous cell carcinoma of the head and neck
Expert Review of Anticancer Therapy, 2018The prognosis of recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (HNSCC) after failure of first line chemotherapy is dismal. Until the publication of the results of CheckMate 141, not a single agent provided any survival benefit as a second line treatment for R/M HNSCC. Areas covered: A comprehensive review of the literature was
openaire +3 more sources